每日振动触觉刺激缓解卒中后痉挛不劣于甚至优于肉毒毒素
这项前瞻性两臂干预研究纳入20例慢性卒中患者,评估VTS手套每日使用3小时、持续8周对痉挛性肌张力增高的效果。结果显示改良Ashworth和改良Tardieu评分在第8周平均降低0.9和0.7,停止使用4周后降低1.1和0.9;在11例常规使用BTX-A的患者中,6例VTS期间改良Ashworth改善幅度大于BTX-A,8例症状最低水平出现在VTS期间。
要点
- 慢性卒中患者每日使用VTS手套3小时、持续8周可显著降低痉挛评分
- 停止VTS手套使用4周后痉挛改善仍持续甚至进一步扩大
- 超过半数常规使用BTX-A的患者在VTS期间获得等同或更优的症状缓解
核心结论
- 每日VTS手套刺激可缓解卒中后痉挛和肌张力增高,对超过半数常规使用BTX-A的患者提供等同或更优的症状缓解。
研究设计与样本
- 前瞻性两臂干预研究,纳入20例慢性卒中患者(平均年龄54岁,平均卒中病程6.9年)。
- 一组为既往接受BTX-A标准治疗者,在末次注射12周后开始干预;另一组为不使用BTX-A者。
- 参与者被指导每日在家或日常活动中使用VTS手套3小时,持续8周。
- 主要结局为改良Ashworth量表和改良Tardieu量表从基线至第8周(VTS手套使用结束)及第12周(停止使用4周后)的差值。
- 使用BTX-A者在开始VTS手套前12周内也接受评估,以监测BTX-A对痉挛性肌张力增高的效果。
主要发现
- 每日VTS手套使用期间及之后均发现痉挛性肌张力增高的临床有意义差异。
- 第8周时改良Ashworth和改良Tardieu评分平均分别降低0.9(P=.0014)和0.7(P=.0003)。
- 停止VTS手套使用1个月后改良Ashworth和改良Tardieu评分平均分别降低1.1(P=.00025)和0.9(P=.0001)。
- 在11例使用BTX-A的参与者中,6例在VTS手套使用期间改良Ashworth评分变化更大(平均-1.8 vs BTX-A平均-1.6)。
- 在11例使用BTX-A的参与者中,8例在VTS手套使用期间症状水平最低(优于BTX-A期间)。
关键数值与推荐
- 改良Ashworth评分在第8周平均降低0.9(P=.0014),停止使用4周后平均降低1.1(P=.00025)。
- 改良Tardieu评分在第8周平均降低0.7(P=.0003),停止使用4周后平均降低0.9(P=.0001)。
- BTX-A组中6/11例VTS期间改良Ashworth变化大于BTX-A期间(平均-1.8 vs 平均-1.6)。
- BTX-A组中8/11例在VTS期间症状水平最低(优于BTX-A期间)。
临床怎么用
- VTS手套可作为慢性卒中患者痉挛管理的可行家庭干预手段,每日使用3小时、持续8周。
- 对常规接受BTX-A治疗的患者,VTS手套可能提供等同或更优的痉挛缓解,可考虑作为辅助或替代选择。
- 停止VTS手套使用后痉挛改善仍可维持至少4周,提示疗效具有持续效应。
局限性
- 研究样本量较小(N=20),结果需更大样本验证。
- 研究为前瞻性两臂干预研究,非随机对照设计,可能存在选择偏倚。
- BTX-A组与不使用BTX-A组之间未进行直接随机比较,组间可比性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the feasibility and efficacy of the VibroTactile Stimulation (VTS) Glove, a wearable device that provides VTS to the impaired limb to reduce spastic hypertonia. DESIGN: Prospective 2-arm intervention study-including 1 group of patients who use Botulinum toxin (BTX-A) for spasticity and 1 group of patients who do not use BTX-A. SETTING: Participants were recruited through rehabilitation and neurology clinics. PARTICIPANTS: Patients with chronic stroke (N=20; mean age=54 years, mean time since stroke=6.9 years). Patients who were previously receiving the standard of care (BTX-A injection) were eligible to participate and started the intervention 12 weeks after their last injection. INTERVENTION: Participants were instructed to use the VTS Glove for 3 hours daily, at home or during everyday activities, for 8 weeks. MAIN OUTCOME MEASURES: Spasticity was assessed with the Modified Ashworth Scale and the Modified Tardieu Scale at baseline and then at 2-week intervals for 12 weeks. Primary outcomes were the difference from baseline and at week 8 (end of VTS Glove use) and week 12 (4 weeks after stopping VTS Glove use). Patients who were receiving BTX-A were also assessed during the 12 weeks preceding the start of VTS Glove use to monitor the effect of BTX-A on spastic hypertonia. Range of motion and participant feedback were also studied. RESULTS: A clinically meaningful difference in spastic hypertonia was found during and after daily VTS Glove use. Modified Ashworth and Modified Tardieu scores were reduced by an average of 0.9 (P=.0014) and 0.7 (P=.0003), respectively, at week 8 of daily VTS Glove use, and by 1.1 (P=.00025) and 0.9 (P=.0001), respectively, 1 month after stopping VTS Glove use. For participants who used BTX-A, 6 out of 11 showed greater change in Modified Ashworth ratings during VTS Glove use (mean=-1.8 vs mean=-1.6 with BTX-A) and 8 out of 11 showed their lowest level of symptoms during VTS Glove use (vs BTX-A). CONCLUSIONS: Daily stimulation from the VTS Glove provides relief of spasticity and hypertonia. For more than half of the participants who had regularly used BTX-A, the VTS Glove provided equal or greater symptom relief.
引用
- Seim C, Chen B, Han C, et al. Daily Vibrotactile Stimulation Exhibits Equal or Greater Spasticity Relief Than Botulinum Toxin in Stroke. Arch Phys Med Rehabil. 2023. PMID: 37149017. doi:10.1016/j.apmr.2023.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。